Shots:

• The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm- 120mg & 240mg) vs PBO in 1-700 patients with low (4 to<8 monthly migraine headache days) and high (8-14 monthly migraine headache days) frequency episodic migraine
• The collective studies result demonstrated improvement in both subgroups with mean % of patients with ≥50%- ≥75% and ≥100% reduction from baseline in overall monthly migraine headache days  
• Emgality (galcanezumab-gnlm) is a mAb- targeting calcitonin gene-related peptide (CGRP) has received FDA’s & EU’s approval in Sept’18 & Nov’18 for treatment & prophylaxis of migraine in adults with at least 4 migraine days/mos. respectively

Ref: Eli Lilly | Image: Eli Lilly